Changxue Lu

Medicine & Life Sciences

1. Androgen Receptors 100%
2. Prostatic Neoplasms 94%
3. Castration 85%
4. MDV 3100 70%
5. Thyroid Hormone Receptors 54%
6. abiraterone 53%
7. Circulating Neoplastic Cells 46%
8. Thyroid Neoplasms 35%
9. Phosphatidylinositol 3-Kinase 24%
10. Co-Repressor Proteins 23%
11. Follicular Adenocarcinoma 22%
12. Thyroid Gland 22%
13. Prostate-Specific Antigen 18%
14. Cytoplasmic and Nuclear Receptors 18%
15. taxane 18%
16. Neoplasms 17%
17. Androgens 16%
18. Carcinogenesis 15%
19. Schistosoma mansoni 14%
20. Growth 14%
21. Ligands 13%
22. TOR Serine-Threonine Kinases 12%
23. Thyroid Hormone Resistance Syndrome 12%
24. Neoplasm Metastasis 11%
25. Therapeutics 10%
26. Progression-Free Survival 10%
27. bosutinib 10%
28. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10%
29. Phenelzine 9%
30. RNA 9%
31. Clorgyline 9%
32. Thyrotropin 9%
33. Cell Proliferation 8%
34. Thyroid Hormones 8%
35. Salivary Ducts 8%
36. Catenins 8%
37. Survival 8%
38. Leukapheresis 8%
39. 70-kDa Ribosomal Protein S6 Kinases 8%
40. Messenger RNA 8%
41. In Situ Hybridization 7%
42. Mechanistic Target of Rapamycin Complex 1 7%
43. Monoamine Oxidase Inhibitors 7%
44. Mutation 7%
45. Peroxisome Proliferator-Activated Receptors 7%
46. Adipogenesis 7%
47. Hormones 7%
48. Drug Therapy 6%